全文获取类型
收费全文 | 21316篇 |
免费 | 1943篇 |
国内免费 | 426篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 439篇 |
妇产科学 | 527篇 |
基础医学 | 1230篇 |
口腔科学 | 876篇 |
临床医学 | 2861篇 |
内科学 | 3183篇 |
皮肤病学 | 385篇 |
神经病学 | 1366篇 |
特种医学 | 259篇 |
外国民族医学 | 3篇 |
外科学 | 2079篇 |
综合类 | 1762篇 |
一般理论 | 3篇 |
预防医学 | 1981篇 |
眼科学 | 175篇 |
药学 | 3086篇 |
4篇 | |
中国医学 | 1930篇 |
肿瘤学 | 1431篇 |
出版年
2024年 | 63篇 |
2023年 | 564篇 |
2022年 | 688篇 |
2021年 | 1167篇 |
2020年 | 1044篇 |
2019年 | 1064篇 |
2018年 | 1030篇 |
2017年 | 968篇 |
2016年 | 837篇 |
2015年 | 829篇 |
2014年 | 1844篇 |
2013年 | 2356篇 |
2012年 | 1226篇 |
2011年 | 1201篇 |
2010年 | 948篇 |
2009年 | 933篇 |
2008年 | 1003篇 |
2007年 | 895篇 |
2006年 | 820篇 |
2005年 | 678篇 |
2004年 | 598篇 |
2003年 | 450篇 |
2002年 | 394篇 |
2001年 | 302篇 |
2000年 | 235篇 |
1999年 | 205篇 |
1998年 | 173篇 |
1997年 | 168篇 |
1996年 | 124篇 |
1995年 | 91篇 |
1994年 | 117篇 |
1993年 | 79篇 |
1992年 | 73篇 |
1991年 | 61篇 |
1990年 | 57篇 |
1989年 | 76篇 |
1988年 | 53篇 |
1987年 | 46篇 |
1986年 | 23篇 |
1985年 | 40篇 |
1984年 | 33篇 |
1983年 | 25篇 |
1982年 | 18篇 |
1981年 | 17篇 |
1980年 | 12篇 |
1979年 | 18篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
61.
复方18甲基炔诺酮/雌二醇透皮控释传递系统(LNG/E_2 TCDS)能同时恒速释放低剂量的LNG和E_2,在1周内维持一个平稳而有效的LNG血药浓度。药动学与药效学研究证明,该系统释放的LNG能达到血清LNG目标水平,产生有效的排卵抑制(6/6)。LNG/E_2 TCDS可望发展成为一种安全、有效、非侵入性的新型生育调节避孕制剂。 相似文献
62.
Sintov Amnon Scott William A. Gallagher Kim P. Levy Robert J. 《Pharmaceutical research》1990,7(1):28-33
Epicardial antiarrhythmic drug administration was studied as a therapeutic approach for experimental ventricular tachycardia (VT) in an open-chest dog model. Lidocaine-polyurethane matrices (28%, w/w) were formulated as a model system. Matrices were placed on the left ventricular epicardium in each of 23 anesthetized open-chest dogs with ouabain-induced VT, to evaluate effectiveness in restoring sinus rhythm. Conversion occurred in all animals treated with matrices containing 300 mg or more of lidocaine after 1.5 to 7.0 min. The matrix lidocaine content correlated linearly with the time required for conversion to sinus rhythm (r = 0.75, P = 0.0002); irrespective of matrix size the myocardial/plasma lidocaine ratio was 20.1 ± 4.2 (mean ± SD) at the time of conversion. In a separate series of five dogs without ventricular tachycardia, systolic wall thickening measured with sonomicrometers after 5 min of controlled-release lidocaine administration (500- to 1000-mg matrix lidocaine content, 7.48 ± 3.49-mg/kg dose) was only minimally diminished (–14.1%) and this effect was observed only at the site of matrix placement on the anterior-apical epicardium. In contrast, intracoronary injection of 0.3 or 1.0 mg/kg of lidocaine-HCl resulted in complete elimination of wall thickening or replacement by systolic thinning. Thus epicardial administration of lidocaine from polyurethane matrices was an effective means of treating ouabain-induced ventricular tachycardia. Regional myocardial function in the vicinity of the matrices was modified to a very limited degree, supporting the view that the matrices can be used safely, without serious risk to ventricular contractile performance. 相似文献
63.
Clinical Efficacy of New Antiepileptic Drugs in Refractory Partial Epilepsy: Experience in the United States With Three Novel Drugs 总被引:1,自引:1,他引:0
Jacqueline A. French 《Epilepsia》1996,37(S2):S23-S26
Summary: A number of new antiepileptic drugs (AEDs), including topiramate (TPM), felbamate (FBM), and gabapentin (GBP), are approved or believed to be close to approval for marketing in the United States. Key efficacy findings for these AEDs in refractory partial epilepsy were reviewed. Large and significant drug-placebo differences were observed with TPM in two large dose-finding trials conducted in the United States. The minimal effective dose of TPM in the population studied was determined to be approximately 200 mg/day, and doses above 600 mg/day produced good efficacy but little incremental benefit versus the lower dosages for the overall study population. FBM is active in partial epilepsy, although seizure reduction is less marked and drug interactions complicate the findings. GBP is also active in this population, but only the 1,800 mg/day dosage was significantly better than placebo with respect to percent re-sponders. It may be useful to explore higher dosage ranges for both FBM and GBP if they can be well tolerated. 相似文献
64.
C. J. Bowden W. D. Figg N. A. Dawson O. Sartor R. J. Bitton M. S. Weinberger Donna Headlee Eddie Reed C. E. Myers M. R. Cooper 《Cancer chemotherapy and pharmacology》1996,39(1-2):1-8
Introduction: Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis,
but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent. Objective: This clinical trial of suramin was undertaken as a phase I/II study in patients with hormone-refractory prostate cancer,
with the hypothesis that the intensity of therapy with suramin could be increased significantly if measures were undertaken
to maintain the plasma concentrations of the drug under 300 μg/ml. Methods: We report the clinical results of this trial, wherein patients were treated at three different targeted plasma suramin concentrations
(275, 215 and 175 μg/ml) for varying periods of time (2, 4 or 8 weeks), with delivery of the drug by continuous intravenous
infusion. Results: The major toxicity observed in this trial was neurologic, consisting of a motor and sensory peripheral neuropathy that resulted
in both paresis and paralysis of the limbs. Nearly all of this severe (CTEP grade III, IV) neurologic toxicity was observed
in the patients treated at a plasma suramin concentration of 275 μg/ml for 4 or more weeks. A single patient treated at 215 μg/ml
for 8 weeks developed moderate (CTEP grade III) proximal lower extremity weakness, and no patient treated at 175 μg/ml developed
this toxicity. The second most common toxicity observed was infection of the central venous catheter. The overall response
rate for all of the evaluable patients was 17% (13 of 75 patients). In addition, prostate-specific antigen (PSA)-defined responses
were observed in six patients receiving therapy at 175 μg/ml, but these responses were confounded by cessation of therapy
with flutamide during suramin treatment. Conclusions: In summary, although plasma suramin concentrations were maintained below 300 μg/ml, neurologic toxicity nonetheless occurred
with high frequency in patients treated at 275 μg/ml for 4 or more weeks. Therapy at 215 and 175 μg/ml was in general well
tolerated, but central venous catheter-related infection, as well as the inconvenience and expense of continuous infusional
therapy, make this method of drug delivery impractical. Only moderate antitumor activity was observed during this trial, but
it is possible that both continuation of flutamide and flutamide withdrawal during suramin therapy confounded the assessment
of suramin’s activity in hormone-refractory prostate cancer.
Received: 9 June 1995/Accepted: 18 March 1996 相似文献
65.
Eros S. Chaves Robert C. Wood Archie A. Jones Dewey A. Newbold Mary A. Manwell Kenneth S. Kornman 《Journal of clinical periodontology》1993,20(2):139-143
Abstract Bleeding on probing (BOP) and the gingival index have been used to clinically characterize the degree of gingival inflammation. It is, however, unclear to what extent these parameters correlate to each other and to probing pocket depth (PD). The purpose of this clinical study was to evaluate the association between BOP and GI bleeding (scores of 2 and 3), as well as the relationship of these variables to PD, in a group of patients presenting with naturally-occurring gingivitis. Based on screening examinations of 125 subjects with at least 20 teeth, no more than 4 sites with PD over 6 mm, a BOP frequency of 30% or greater, and no systemic condition that would influence the inflammatory response, were selected. 2 weeks after screening they were examined at 6 sites per tooth for plaque index, GI, PD and BOP. A standardized pressure sensitive probe (Florida Probe) with 20 g probing force was used for BOP and PD measurements. In this population, means of 40.9% (S.E.= 1.36) BOP sites and 35.3% (S.E, = 1.81) GI bleeding sites per patient were found. A total of 20,008 sites ranging in PD up to 5.9 mm were evaluated; however, the majority of sites (19,723, 98.6%) presented with <4 mm PD. When sites were evaluated, BOP demonstrated a positive correlation with PD, whereas GI bleeding correlated with PH. For sites characterized by the absence of BOP as well as the absence of GI bleeding (scores 0 and 1), the highest % of agreement between the 2 indices (77.7%) was found in shallow sites (0.1–2 mm). In contrast, when sites presenting with both BOP and GI bleeding were analyzed, the highest % of agreement (85,4%) was found for sites with PD >4.0 mm. In this gingivitis population group, it appears that BOP and GI bleeding evaluate distinct inflammatory1 conditions of the gingival tissues, and the relationship between the 2 clinical parameters may vary according to PD at the individual site examined. 相似文献
66.
H. -J. Möller H. M. van Praag B. Aufdembrinke P. Bailey T. R. E. Barnes J. Beck H. Bentsen F. X. Eich L. Farrow W. W. Fleischhacker J. Gerlach K. Grafford B. Hentschel A. Hertkorn S. Heylen Y. Lecrubier J. P. Leonard P. McKenna W. Maier V. Pedersen A. Rappard W. Rein J. Ryan M. Sloth Nielsen R. -D. Stieglitz G. Wegener J. Wilson 《Psychopharmacology》1994,115(1-2):221-228
There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all influence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally. 相似文献
67.
甲磺酸帕珠沙星注射液治疗急性细菌性感染有效性和安全性的多中心临床研究 总被引:1,自引:0,他引:1
目的评价甲磺酸帕珠沙星注射液治疗急性细菌性呼吸系统、泌尿生殖系统感染的有效性、安全性。方法采用随机单盲平行对照多中心试验方法。选择急性细菌性呼吸系统、泌尿生殖系统感染患者213例,可评价病例209例,随机编人试验组或对照组。试验组101例.每日1次给予甲磺酸帕珠沙星注射液300mg,iv,gtt,bid;对照组108例,每日1次给予加替沙星注射液200mg,iv,gtt,bid。疗程7~10d。结果甲磺酸帕珠沙星组、加替沙星组有效率分别为94.06%(95/101)和90.74%(98/108);痊愈率分别为67.33%(68/101)和70.37%(76/108);细菌清除率分别为94.62%(88/93)和93.62%(88/94);不良反应发生率分别为7,69%(8/104)和5.50%(6/109)。两组有效性、安全性相似(P〉0.05)。结论甲磺酸帕珠沙星注射液治疗急性细菌性呼吸系统、泌尿生殖系统感染有效、安全,与加替沙星相当。 相似文献
68.
目的:利用单光子发射计算机断层摄影(SPECT)半定量分析有效控制与控制不良的MRI阴性的全面性强直阵挛发作癫(GTCS)病人的局部脑血流差异,探讨脑血流灌注与其预后的关系.材料和方法:对29例有效控制的和12例控制不佳的MRI阴性的GTCS病人进行发作间期99mTc-ECD-SPECT脑血灌流显像,10例年龄匹配的健康人作对照,用感兴趣区(ROI)的不对称指数(%AI)进行半定量分析.将SPECT分析结果与病人的临床表现与EEG相比较.结果:①控制不佳组与有效控制组在丘脑和基底节区的%AI存在显著性差异(P<0.05);②控制不佳组SPECT脑显像的异常率(83.3%,10/12)明显高于有效控制组的异常率(17.2%,5/29),两组具有显著性差异(P<0.01);而两组病人的EEG异常率分别为58.3%、44.8%(7/12、13/29),无显著性差异(P>0.05).结论:控制不佳的MRI阴性的GTCS病人往往存在发作间期的低血流灌注脑区,提示癫的难治性;而控制良好的病人多无明显异常发现,可能预后较好. 相似文献
69.
70.